Forget cannabis edibles and cannabis leaf products. The big story right now is cannabidiol, or CBD.

Hemp is now legal in the U.S. And the most lucrative opportunity resulting from this legalization is with hemp-derived CBD products. Cannabis market researcher Brightfield Group projects that the U.S. hemp CBD market will total $22 billion by 2022. A more conservative estimate comes from investment firm Piper Jaffray, which forecasts annual U.S. hemp CBD sales of close to $15 billion by 2023.

In the context of what’s going on in the market today, i.e., trade uncertainties, an inverted yield curve, a heavily indebted consumer, and general global malaise, a 14% drop in the stock price of Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) is nothing to be shocked about.

With the Canadian economy seeing slower than expected GDP growth again, this time coming in at 0.4% compared to expectations of 0.7%, we are seeing more and more to be nervous about.

Here are two things that I would keep in mind when making the decision of whether to buy Canopy Growth stock on weakness.

That old investing adage of "sell in May and go away" might have been good advice to follow for investors in the cannabis industry. Most cannabis stocks performed dismally last month. But not all of them were losers.

Three cannabis stocks managed to achieve solid gains in May: Namaste Technologies(NASDAQOTH:NXTTF) (TSXV:N), Cara Therapeutics (NASDAQ:CARA), and GW Pharmaceuticals(NASDAQ:GWPH). Here's how these stocks bucked the downtrend and whether or not they're smart picks to buy now. 

With the purchase of a local pot producer, a beer and wine company could bring Saskatchewan to the forefront of cannabis-infused beverages.

The Hill Street Beverage Company out of Ontario has signed a letter of intent to buy OneLeaf Cannabis for $16 million.

Terry Donnelly, chairman and CEO of Hill Street, said the company is going to use OneLeaf’s expertise and massive production facility just outside of Regina to help create its upcoming line of weed-infused beers and wines.

“We think this is the equivalent to the end of prohibition of alcohol, so we’re planning a multi-year strategy to be able to create a whole new portfolio or whole new category of beverages that we believe will be an alternative to alcohol,” explained Donnelly.

Following decades of hiding in the shadows, marijuana now finds itself in the spotlight as one of the fastest-growing industries on the planet (especially in North America). Much of this has to do with Canada becoming the first industrialized country in the world to legalize recreational marijuana. According to Wall Street projections, Canada's legal weed industry could net close to $6 billion in sales by 2022.

Could Asia be a potential gold mine for Canadian cannabis producers?  

Marijuana stocks were broadly lower Thursday after MedMen (OTC: MMNFF) revealed it's slashing executive pay amid widening losses. It comes as the FDA is set to hold its first public hearing on CBD, a nonintoxicating cannabis compound claimed to have therapeutic benefits.

MedMen, whose trendy retail outlets resemble Apple stores, posted a loss of $63.1 million, or 20 cents a share, for its fiscal Q3 vs. a year-ago loss of $16.8 million. Analyst were expecting a loss of 10 cents a share, according to Yahoo Finance. Revenue surged 156% to $36.6 million.

Money continues to pour into marijuana stocks at a feverish clip, despite growing fears that legal cannabis cultivators are the latest iteration of a market bubble. While cultivators such as Canopy Growth (TSX:WEED)(NYSE:CGC), Aurora, and Cronos have made outstanding gains of 35%, 58%, and 163%, respectively, over the last year, industry insiders are claiming there is further massive upside ahead and short sellers are circling.

The marijuana industry in Canada is currently evolving at a fast pace. Sales have gone through the roof since recreational use of pot was legalized last year. However, many marijuana companies are choosing to do business south of the border; after all, the U.S. is the largest market in the world. Let’s look at two U.S.-focused pot companies investors should keep an eye on: Curaleaf Holdings(CNSX:CURA) and Charlotte’s Web Holdings (CSNX:CWEB). Which is the better buy?

The case for Curaleaf Holdings

Investors not yet familiar with Curaleaf should catch up; the Vancouver-based firm recently announced the largest U.S.-focused acquisition in the marijuana industry to date.

Traffic stats don’t lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But what exactly is this three-letter acronym, and how can CBD stocks boost your returns?

Let’s start with basic definitions. Cannabidiol represents one of several cannabinoids, or chemical compounds found in the cannabis sativa plant. But unlike the most famous cannabinoid tetrahydrocannabinol (THC), CBD does not trigger any psychoactive effect. In other words, users can enjoy this compound’s benefits without getting high.